278 related articles for article (PubMed ID: 11786417)
1. Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations.
Chazaud B; Ricoux R; Christov C; Plonquet A; Gherardi RK; Barlovatz-Meimon G
Am J Pathol; 2002 Jan; 160(1):237-46. PubMed ID: 11786417
[TBL] [Abstract][Full Text] [Related]
2. Involvement of the [uPAR:uPA:PAI-1:LRP] complex in human myogenic cell motility.
Chazaud B; Bonavaud S; Plonquet A; Pouchelet M; Gherardi RK; Barlovatz-Meimon G
Exp Cell Res; 2000 Aug; 258(2):237-44. PubMed ID: 10896774
[TBL] [Abstract][Full Text] [Related]
3. Wound-induced migration of MDA-MB-435 and SKOV-3 cancer cells is regulated by plasminogen activator inhibitor-1.
Whitley BR; Church FC
Int J Oncol; 2005 Sep; 27(3):749-57. PubMed ID: 16077925
[TBL] [Abstract][Full Text] [Related]
4. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
6. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
[TBL] [Abstract][Full Text] [Related]
7. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
[TBL] [Abstract][Full Text] [Related]
8. Urokinase-type plasminogen activator system and breast cancer (Review).
Han B; Nakamura M; Mori I; Nakamura Y; Kakudo K
Oncol Rep; 2005 Jul; 14(1):105-12. PubMed ID: 15944776
[TBL] [Abstract][Full Text] [Related]
9. Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells.
Whitley BR; Palmieri D; Twerdi CD; Church FC
Exp Cell Res; 2004 Jun; 296(2):151-62. PubMed ID: 15149846
[TBL] [Abstract][Full Text] [Related]
10. EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor.
Henic E; Sixt M; Hansson S; Høyer-Hansen G; Casslén B
Gynecol Oncol; 2006 Apr; 101(1):28-39. PubMed ID: 16263158
[TBL] [Abstract][Full Text] [Related]
11. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity.
Czekay RP; Kuemmel TA; Orlando RA; Farquhar MG
Mol Biol Cell; 2001 May; 12(5):1467-79. PubMed ID: 11359936
[TBL] [Abstract][Full Text] [Related]
12. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
Grøndahl-Hansen J; Christensen IJ; Briand P; Pappot H; Mouridsen HT; Blichert-Toft M; Danø K; Brünner N
Clin Cancer Res; 1997 Feb; 3(2):233-9. PubMed ID: 9815678
[TBL] [Abstract][Full Text] [Related]
14. Signalling networks associated with urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in breast cancer tissues: new insights from protein microarray analysis.
Wolff C; Malinowsky K; Berg D; Schragner K; Schuster T; Walch A; Bronger H; Höfler H; Becker KF
J Pathol; 2011 Jan; 223(1):54-63. PubMed ID: 21125664
[TBL] [Abstract][Full Text] [Related]
15. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
[TBL] [Abstract][Full Text] [Related]
16. A structural basis for differential cell signalling by PAI-1 and PAI-2 in breast cancer cells.
Croucher DR; Saunders DN; Stillfried GE; Ranson M
Biochem J; 2007 Dec; 408(2):203-10. PubMed ID: 17696882
[TBL] [Abstract][Full Text] [Related]
17. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
[TBL] [Abstract][Full Text] [Related]
18. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H
Cancer Res; 1994 May; 54(10):2527-30. PubMed ID: 8168072
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins.
Czekay RP; Aertgeerts K; Curriden SA; Loskutoff DJ
J Cell Biol; 2003 Mar; 160(5):781-91. PubMed ID: 12615913
[TBL] [Abstract][Full Text] [Related]
20. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation.
Kjøller L; Kanse SM; Kirkegaard T; Rodenburg KW; Rønne E; Goodman SL; Preissner KT; Ossowski L; Andreasen PA
Exp Cell Res; 1997 May; 232(2):420-9. PubMed ID: 9168821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
